| Published Application/Species/Sample/Dilution | Reference |
|---|
- immunohistochemistry; human; loading ...; tbl 2
| Kumar M, Guleria B, Swamy S, Soni S. Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer. Lung India. 2020;37:145-150 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 1f
| Cao Y, Chan K, Xiao G, Chen Y, Qiu X, Hao H, et al. Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma. BMC Cancer. 2019;19:1022 pubmed publisher |
- immunohistochemistry; human; fig 5a
| Song T, Nairismägi M, Laurensia Y, Lim J, Tan J, Li Z, et al. Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma. Blood. 2018;: pubmed publisher |
- immunohistochemistry - paraffin section; human; 1:4; loading ...; fig 1
| Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery. 2018;: pubmed publisher |
- immunohistochemistry - paraffin section; human; fig 2d
- western blot; human; 1:300; fig 1b
| Haffner M, Guner G, Taheri D, Netto G, Palsgrove D, Zheng Q, et al. Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. Am J Pathol. 2018;188:1478-1485 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 2f
- western blot; human; 1:500; loading ...; fig 2f
| Parra E, Villalobos P, Mino B, Rodriguez Canales J. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol. 2018;26:83-93 pubmed publisher |
- immunohistochemistry - paraffin section; human; loading ...; fig 1
| Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, et al. PD-L1 Status in Refractory Lymphomas. PLoS ONE. 2016;11:e0166266 pubmed publisher |
| Morsch R, Rose M, Maurer A, Cassataro M, Braunschweig T, Knüchel R, et al. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer. 2020;20:230 pubmed publisher |
| Noh B, Kwak J, Eom D. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma. BMC Cancer. 2020;20:58 pubmed publisher |
| Yoon H, Park H, Cho M, Shim S, Kim Y, Lee J. Spontaneous remission of advanced progressive poorly differentiated non-small cell lung cancer: a case report and review of literature. BMC Pulm Med. 2019;19:210 pubmed publisher |
| Wang Y, Wenzl K, Manske M, Asmann Y, Sarangi V, Greipp P, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019;9:73 pubmed publisher |
| Tsunoda A, Morikawa K, Inoue T, Miyazawa T, Hoshikawa M, Takagi M, et al. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. BMC Cancer. 2019;19:546 pubmed publisher |
| Vigliar E, Malapelle U, Bono F, Fusco N, Cortinovis D, Valtorta E, et al. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. Biomed Res Int. 2019;2019:6832909 pubmed publisher |
| . Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1103-1115 pubmed publisher |
| Bahig H, Aubin F, Stagg J, Gologan O, Ballivy O, Bissada E, et al. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma. BMC Cancer. 2019;19:68 pubmed publisher |
| Ma J, Li J, Qian M, Han W, Tian M, Li Z, et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N). Diagn Pathol. 2018;13:91 pubmed publisher |
| . 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018;6:114 pubmed publisher |
| Kowanetz M, Zou W, Gettinger S, Koeppen H, Kockx M, Schmid P, et al. Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci U S A. 2018;115:E10119-E10126 pubmed publisher |
| Tatlı Doğan H, Kıran M, Bilgin B, Kilicarslan A, Sendur M, Yalcin B, et al. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression. Diagn Pathol. 2018;13:60 pubmed publisher |
| Scorer P, Scott M, Lawson N, Ratcliffe M, Barker C, Rebelatto M, et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagn Pathol. 2018;13:47 pubmed publisher |
| Dieci M, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, et al. Immune characterization of breast cancer metastases: prognostic implications. Breast Cancer Res. 2018;20:62 pubmed publisher |
| Vari F, Arpon D, Keane C, Hertzberg M, Talaulikar D, Jain S, et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131:1809-1819 pubmed publisher |
| Liang X, Sun J, Wu H, Luo Y, Wang L, Lu J, et al. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Diagn Pathol. 2018;13:5 pubmed publisher |
| Suda K, Rozeboom L, Furugaki K, Yu H, Melnick M, Ellison K, et al. Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. Biomed Res Int. 2017;2017:7694202 pubmed publisher |
| Seo A, Kang B, Kwon O, Park K, Lee S, Chung H, et al. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Br J Cancer. 2017;117:1753-1760 pubmed publisher |
| Syed Y. Durvalumab: First Global Approval. Drugs. 2017;77:1369-1376 pubmed publisher |
